The European Medicines Agency Experience with Biomarker Qualification

  • Efthymios ManolisEmail author
  • Armin Koch
  • Dieter Deforce
  • Spiros Vamvakas
Part of the Methods in Molecular Biology book series (MIMB, volume 1243)


Since the launch of the qualification process in 2009, the CHMP reviewed/is reviewing 48 requests for qualification advice or opinion (as of Sept 2013) related to biomarkers (BM) or other novel drug development tools (e.g. patient reported outcome measures, modeling, and statistical methods). The qualification opinions are available on the EMA website (Qualification of novel methodologies for medicine development,, 2013). Also there is a trend of increasing numbers of qualification requests to CHMP, indicative of the pace that targeted drug development and personalized medicine is gaining and the need to bring the new tools from research to drug development and clinical use. This chapter will focus on the regulatory experience gained so far from the CHMP qualification procedure. Basic qualification principles will be presented. Through qualification examples, we will elaborate on common grounds and divergences between the different stakeholders.

Key words

Qualification Biomarkers Regulatory EMA 



The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.


  1. 1.
    Mischak H, Ioannidis JP, Argiles A et al (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42:1027–1036PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
  3. 3.
  4. 4.
    Manolis E, Vamvakas S, Isaac M (2011) New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl 5:248–255PubMedCrossRefGoogle Scholar
  5. 5.
    International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use concept paper on pharmacogenomic biomarker qualification: format and data standards. Accessed 30 Sept 2013
  6. 6.
    Guideline on clinical evaluation of diagnostic agents. Accessed 30 Sept 2013
  7. 7.
    Reflection paper on pharmacogenomic samples, testing and data handling. Accessed 30 Sept 2013
  8. 8.
    Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. Accessed 30 Sept 2013
  9. 9.
    Ziegler A, Koch A, Krockenberger K et al (2012) Personalized medicine using DNA biomarkers: a review. Hum Genet 131:1627–1638PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    ICH topic E 9 statistical principles for clinical trials. Accessed 30 Sept 2013
  11. 11. Accessed 30 Sept 2013
  12. 12.
    EMA points to consider on application with 1. meta-analysis; 2. one pivotal study. Accessed 30 Sept 2013
  13. 13.
    Reflection paper on risk based quality management in clinical trials. Accessed 30 Sept 2013
  14. 14.
    Qualification opinion ILSI/HESI submission of novel renal biomarkers for toxicity. Accessed 30 Sept 2013

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Efthymios Manolis
    • 1
    Email author
  • Armin Koch
    • 1
    • 2
  • Dieter Deforce
    • 1
    • 3
  • Spiros Vamvakas
    • 1
  1. 1.European Medicines AgencyLondonUK
  2. 2.Medizinische Hochschule HannoverInstitut für BiometrieHannoverGermany
  3. 3.Ghent University, Laboratory of Pharmaceutical BiotechnologyGhentBelgium

Personalised recommendations